(Q47366851)

English

Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial

scientific article published on 11 July 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Christoph Correll

5

object named as

Christoph U Correll

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Jürgen Zielasek

4

object named as

Jürgen Zielasek

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Wolfgang Gaebel

10

object named as

Wolfgang Gaebel

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

author name string

Joachim Cordes

1

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Johanna Thünker

2

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Gunnar Regenbrecht

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Christian Schmidt-Kraepelin

6

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Christian Lange-Asschenfeldt

7

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Marcus W Agelink

8

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Kai G Kahl

9

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Ansgar Klimke

11

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Hans Hauner

12

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

publication date

11 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

15

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

3

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

229-241

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Medication-induced weight gain and dyslipidemia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Factors associated with weight gain with olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Weight change with atypical antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Olanzapine: review of safety 2008

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Statistical properties of randomization in clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Antipsychotic drug effects on brain morphology in first-episode psychosis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Obesity in patients with severe mental illness: overview and management

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Validity of WHO criteria for classification of newly diagnosed diabetics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Hippocampal plasticity in response to exercise in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

A program for managing weight gain associated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.592546

21 January 2018

Identifiers

10.3109/15622975.2011.592546

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 January 2018

http://europepmc.org/abstract/MED/21745127

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47366851&oldid=2153776028"